Lupin Launches Generic Myfortic Delayed-release Tablets

Pharma major Lupin Limited announced the launch of mycophenolic acid delayed release tablets USP, 180 mg and 360 mg.Lupin’s alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (FDA) earlier.Mycophenolic acid delayed-release tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic delayed-release tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation, and are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant and use in combination with cyclosporine and corticosteroids.Mycophenolic acid delayed-release tablets USP had an annual sales of approximately US$ 156 million in the US (IQVIA MAT February 2020).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!